Efficacy and safety of recombinant tissue plasminogen activator for venous thrombosis after paediatric heart surgery

Reports in the literature of treatment with recombinant tissue plasminogen activator following cardiac surgery are limited. We reviewed our experience to provide a case series of the therapeutic use of tissue plasminogen activator for the treatment of venous thrombosis in children after cardiac surg...

Full description

Saved in:
Bibliographic Details
Published in:Cardiology in the young 2018-02, Vol.28 (2), p.214-221
Main Authors: Justice, Lindsey B., Nelson, David P., Palumbo, Joseph, Sawyer, Jaclyn, Patel, Manish N., Byrnes, Jonathan W.
Format: Article
Language:English
Subjects:
Age
Bats
Blood clots
Cardiovascular disease
Catheters
Children
Congenital diseases
Heart
Heart surgery
Infants
Medical records
Molecular weight
Morbidity
Mortality
Original Articles
Patients
Pediatrics
Postoperative period
Surgery
Surgical drains
Systematic review
t-Plasminogen activator
Thromboembolism
Thrombosis
Tubes
Veins & arteries
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Reports in the literature of treatment with recombinant tissue plasminogen activator following cardiac surgery are limited. We reviewed our experience to provide a case series of the therapeutic use of tissue plasminogen activator for the treatment of venous thrombosis in children after cardiac surgery. The data describe the morbidity, mortality, and clinical outcomes of tissue plasminogen activator administration for treatment of venous thrombosis in children following cardiac surgery. The study was designed as a retrospective case series. The study was carried out in a 25-bed cardiac intensive care unit in an academic, free-standing paediatric hospital. Patients All children who received tissue plasminogen activator for venous thrombosis within 60 days of cardiac surgery, a total of 13 patients, were included. Interventions Data was collected, collated, and analysed as a part of the interventions of this study. Measurements and main results Patients treated with tissue plasminogen activator were principally young infants (median 0.2, IQR 0.07-0.58 years) who had recently (22, IQR 12.5-27.3 days) undergone cardiac surgery. Hospital mortality was high in this patient group (38%), but there was no mortality attributable to tissue plasminogen activator administration, occurring within
ISSN:1047-9511
1467-1107
DOI:10.1017/S104795111700172X